Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Konzern Hauptsitz Basel Switzerland 4070
- IPO Date
- Aug 20, 2003
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG, headquartered in Basel, Switzerland and founded in 1896, operates as one of the world's largest biotechnology companies and the global leader in in-vitro diagnostics; it develops and markets innovative medicines and diagnostic products across oncology, immunology, infectious diseases, ophthalmology, neuroscience, hematology, respiratory diseases, cardiovascular, renal and metabolic disorders, rare diseases, and women's health, with key pharmaceutical brands including Avastin, MabThera/Rituxan, Herceptin, Perjeta, Tecentriq, Hemlibra, Ocrevus, and Vabysmo; its diagnostics portfolio encompasses in-vitro diagnostics, point-of-care testing such as the recently FDA-cleared CLIA-waived test for Bordetella infections including whooping cough, continuous glucose monitoring systems, cell analysis, gene expression, genome sequencing, and nucleic acid purification technologies; the company serves customers worldwide through operations in more than 130 countries, with significant presence via wholly-owned Genentech in the United States and majority stake in Japan's Chugai Pharmaceutical. Roche maintains two primary segments, Pharmaceuticals and Diagnostics, targeting healthcare providers, researchers, and patients with personalized healthcare solutions that integrate data insights from clinical practice. Recent developments include a definitive merger agreement in September 2025 to acquire 89bio for up to $3.5 billion to bolster its cardiovascular, renal, and metabolic portfolio with pegozafermin for moderate to severe MASH; a $50 billion investment commitment over five years announced in April 2025 to expand U.S. R&D and manufacturing in states including Indiana, Pennsylvania, Massachusetts, and California, creating over 12,000 jobs; a $550 million expansion of its Indianapolis diagnostics site for continuous glucose monitoring by 2030; prior acquisitions such as Carmot Therapeutics in 2024, Televant Holdings for $7.1 billion in 2023, and partnerships like those with Innovent Biologics and Poseida Therapeutics; and 53 new collaboration agreements in 2024 alongside ongoing M&A firepower of about $10 billion annually.
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
FDA approves first generic version of Roche's flu drug
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
Nurix Therapeutics Deal With Roche Is Worth Betting On
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
Roche sticks to German investment after Eli Lilly cuts
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Nurix Therapeutics Stock Pops on Roche Partnership
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology